BioCentury
ARTICLE | Clinical News

ARGX-111: Phase Ib data

June 22, 2015 7:00 AM UTC

Data from 18 patients with advanced solid tumors overexpressing c-MET in a dose-escalation, Belgian Phase Ib trial showed that the maximum tolerated dose (MTD) of IV ARGX-111 is 3 mg/kg every 3 weeks....